The CEO Corner platform was launched in March 2024 to provide an additional and in-depth perspective on press releases, corporate developments, and development pipeline progress.

“Keeping our stakeholders well informed is absolutely essential to the future success of AIM ImmunoTech. CEO Corner is a new way for us to connect directly with both current and potential stockholders. CEO Corner segments will provide expanded perspective on press releases, clinical trials and other corporate advancements as we continue to push forward with our development pipeline. We believe in the future of Ampligen and are dedicated to growing value for all stakeholders," said CEO Tom Equels.

March 7, 2024 –
Welcome to the AIM CEO Corner

March 13, 2024 –
Oncology Overview

March 20, 2024 –
Ovarian Cancer

March 20, 2024 –
Virtual Investor Lunch Break: The AIM Opportunity

April 11, 2024 –
Top-line Interim Data from Recurrent Ovarian Cancer Study

Videos Source: Company Reports

• Generally well-tolerated with over 100,000 IV doses in humans

• Clinically tested in oncology as a single-agent therapeutic and in combination with other agents

• Potential in oncology to enhance the efficacy of PD-1 and PD-L1 checkpoint inhibitors¹

• Phase 3 in ME/CFS completed in U.S. – NDA filing pending confirmatory Phase 3 following complete response letter; Approved for the treatment of severe CFS in Argentina

1: Animal experiments support expectations of human responses

Source: Company Reports

Additionally, Ampligen^® induces a wide range of immunologic and anti-tumor activities, making it a potentially useful immuno-therapy targeting multiple cancers with high unmet needs.

Source: Company Reports

Source: Company Reports

Next Steps:

AIM ImmunoTech reports ongoing positive developments in its cancer treatment programs with Ampligen. Following initial promising data in 2022, recent studies have shown enhanced anti-tumor immunity in recurrent ovarian cancer as of April 2024. Additionally, positive findings from the study of Ampligen in pancreatic cancer have been published in the Journal of Clinical Cancer Research in March 2024. The company continues to explore and expand Ampligen’s therapeutic potential across various oncological applications.

In the video below, CEO Thomas Equels joined Proactive's Stephen Gunnion after the company announced the start of an NCI-funded Phase 2 study of its product candidate, Ampligen, in melanoma. Equels gave an overview of Ampligen and explained the process for the Phase 2 study and the steps AIM will take if it is successful. He also provided an overview of AIM's other programs with Ampligen.

Alferon N Injection® continues to be an FDA-approved treatment for refractory or recurrent external condylomata acuminata. The commercial relaunch is pending the completion of the FDA's manufacturing approval process. Sales are expected to resume following a successful pre-approval inspection and obtaining the necessary supplemental approvals.

AIM ImmunoTech has developed strategic partnerships with groups such as the University of Pittsburgh Medical Center as well as Erasmus MC in Rotterdam for their oncology treatment trials.

Source: Company Reports

Source: Company Reports

AIM ImmunoTech believes that it has potential solutions for a number of different indications, both for use in isolation as well as in conjunction with another drug.

First, Ampligen is in late-stage trials for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Up to 2.5 million Americans are estimated to suffer from this malady, causing the U.S. economy an estimated $17 to $24 billion per year, according to the CDC.

Additionally, Ampligen is currently being studied for alleviating "long COVID"—the long-term issues some COVID patients suffer from. While there is not much long-term information to draw from, a recent UCLA study implies that around 30% of COVID patients have long-term symptoms.

Lastly, oncology: AIM ImmunoTech believes that it may have therapeutic solutions for numerous types of cancer. As a malady that impacts so many of us, the potential market for these therapeutics is enormous. Precedence Research estimates that the global market will balloon to over $580 billion annually in 2030, with a Compounded Annual Growth Rate (CAGR) of 8.2% this decade.

Source: Precedence Research

Source: Company Reports

For biotech companies, securing sufficient funding is crucial to sustain development and regulatory approval processes, which are both time-intensive and costly. A lack of adequate funding is a common hurdle that prevents many biotech firms from bringing their candidates to market.

As of the end of 2023, AIM ImmunoTech is in a favorable position compared to many of its peers. With cash and cash equivalents of approximately $13.1 million, the company remains strategically poised with enough financial resources to pursue its clinical development goals and move towards the commercialization of its products.

Source: Company Documents

While a strong cash position is no guarantee that its candidates will successfully move through the regulatory approval process, its cash position combined with a strong intellectual property stack puts it in a strong position for future success.

Source: Company Reports

This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.

AIM ImmunoTech Inc. (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.

Information and opinions presented in the Company Presentation are provided by the Company, and makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment. 

Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.

A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.

Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.

b2i digital or its related entities may own securities of the Company.

The Company is a client of b2i Digital. The Company agreed to pay b2i Digital no greater than $100,000 in cash for 12 months of digital marketing consulting and investor awareness services.

This communication includes forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks, uncertainties and other factors. The Company urges readers to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this communion. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this communication.